(Sharecast News) - Theracryf said on Thursday that initial toxicology data from its lead Ox-1 blocker addiction programme showed the drug was well tolerated at very high doses, as clinical trial-enabling work continued ahead of plan.
The AIM-traded biotech, which is developing treatments for addiction and other neuropsychiatric disorders, said dosing...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE